Found: 622
Select item for more details and to access through your institution.
New pharmacological approaches to diabetes management.
- Published in:
- Practice Nursing, 2015, v. 26, n. 3, p. 140, doi. 10.12968/pnur.2015.26.3.140
- By:
- Publication type:
- Article
Combined metformin-associated lactic acidosis and euglycemic ketoacidosis.
- Published in:
- Wiener Klinische Wochenschrift, 2017, v. 129, n. 17/18, p. 646, doi. 10.1007/s00508-017-1251-6
- By:
- Publication type:
- Article
Effect of Peroral Administration of Chromium on Insulin Signaling Pathway in Skeletal Muscle Tissue of Holstein Calves.
- Published in:
- Biological Trace Element Research, 2017, v. 180, n. 2, p. 223, doi. 10.1007/s12011-017-1007-1
- By:
- Publication type:
- Article
Dose-dependent renoprotection efficacy of sglt2 inhibitors in type 2 diabetes: systematic review and network meta-analysis.
- Published in:
- Acta Diabetologica, 2023, v. 60, n. 10, p. 1311, doi. 10.1007/s00592-023-02126-8
- By:
- Publication type:
- Article
Abrogation of postprandial triglyceridemia with dual PPAR α/γ agonist in type 2 diabetes mellitus: a randomized, placebo-controlled study.
- Published in:
- Acta Diabetologica, 2020, v. 57, n. 7, p. 809, doi. 10.1007/s00592-020-01487-8
- By:
- Publication type:
- Article
Impact of variations in duodenal glucose load on insulin clearance in health and type 2 diabetes.
- Published in:
- Acta Diabetologica, 2018, v. 55, n. 2, p. 205, doi. 10.1007/s00592-017-1073-z
- By:
- Publication type:
- Article
Toe amputations with SGLT-2 inhibitors: data from randomized clinical trials.
- Published in:
- Acta Diabetologica, 2017, v. 54, n. 4, p. 411, doi. 10.1007/s00592-016-0928-z
- By:
- Publication type:
- Article
Ex vivo permeability study and in vitro solubility characterization of oral Canagliflozin self-nanomicellizing solid dispersion using Soluplus<sup>®</sup> as a nanocarrier.
- Published in:
- Acta Marisiensis. Seria Medica, 2024, v. 70, n. 2, p. 42, doi. 10.2478/amma-2024-0011
- By:
- Publication type:
- Article
Systematic Screening Study for the Selection of Proper Stabilizers to Produce Physically Stable Canagliflozin Nanosuspension by Wet Milling Method.
- Published in:
- Bioengineering (Basel), 2023, v. 10, n. 8, p. 927, doi. 10.3390/bioengineering10080927
- By:
- Publication type:
- Article
A study of canagliflozin on post prandial blood sugar control.
- Published in:
- Indian Journal of Basic & Applied Medical Research, 2021, v. 10, n. 3, p. 18, doi. 10.36848/IJBAMR/2020/29215.55560
- By:
- Publication type:
- Article
Canagliflozin Increases Intestinal Adenoma Burden in Female ApcMin/+ Mice.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Use of the SGLT2 inhibitor canagliflozin for control of refractory equine hyperinsulinemia and laminitis.
- Published in:
- Open Veterinary Journal, 2022, v. 12, n. 4, p. 511, doi. 10.5455/OVJ.2022.v12.i4.14
- By:
- Publication type:
- Article
Comparative Genitourinary Safety of In-class Sodium-Glucose Cotransporter-2 Inhibitors among Patients with Heart Failure with Preserved Ejection Fraction: A Cohort Study.
- Published in:
- American Journal of Cardiovascular Drugs, 2024, v. 24, n. 3, p. 455, doi. 10.1007/s40256-024-00648-2
- By:
- Publication type:
- Article
Canagliflozin, an Inhibitor of the Na + -Coupled D-Glucose Cotransporter, SGLT2, Inhibits Astrocyte Swelling and Brain Swelling in Cerebral Ischemia.
- Published in:
- Cells (2073-4409), 2023, v. 12, n. 18, p. 2221, doi. 10.3390/cells12182221
- By:
- Publication type:
- Article
Efficacy and safety of sodium–glucose co‐transporter‐2 inhibitors in kidney transplant recipients with diabetes mellitus.
- Published in:
- Diabetic Medicine, 2024, v. 41, n. 8, p. 1, doi. 10.1111/dme.15383
- By:
- Publication type:
- Article
Canagliflozin or acarbose versus placebo to ameliorate post‐bariatric hypoglycaemia – The HypoBar I randomized clinical trial protocol.
- Published in:
- Diabetic Medicine, 2024, v. 41, n. 6, p. 1, doi. 10.1111/dme.15320
- By:
- Publication type:
- Article
The antidiabetic SGLT2 inhibitor canagliflozin reduces mitochondrial metabolism in a model of skeletal muscle insulin resistance.
- Published in:
- Diabetic Medicine, 2024, v. 41, n. 5, p. 1, doi. 10.1111/dme.15271
- By:
- Publication type:
- Article
Poster abstracts.
- Published in:
- Diabetic Medicine, 2024, v. 41, p. 1, doi. 10.1111/dme.15296
- Publication type:
- Article
Clinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney disease.
- Published in:
- Diabetic Medicine, 2022, v. 39, n. 4, p. 1, doi. 10.1111/dme.14769
- By:
- Publication type:
- Article
Basic and clinical science posters: Vascular and endothelial function.
- Published in:
- Diabetic Medicine, 2021, v. 38, p. 1, doi. 10.1111/dme.22_14556
- Publication type:
- Article
Renal outcomes with the newer antidiabetes drugs: the era before and after CREDENCE.
- Published in:
- Diabetic Medicine, 2020, v. 37, n. 4, p. 593, doi. 10.1111/dme.14262
- By:
- Publication type:
- Article
SGLT2 inhibitors in Type 1 diabetes: is this the future?
- Published in:
- Diabetic Medicine, 2018, v. 35, n. 12, p. 1642, doi. 10.1111/dme.13791
- By:
- Publication type:
- Article
Unmasking and aggravation of polycythemia vera by canagliflozin.
- Published in:
- Diabetic Medicine, 2018, v. 35, n. 11, p. 1613, doi. 10.1111/dme.13706
- By:
- Publication type:
- Article
Glycaemic efficacy of canagliflozin is largely independent of baseline β-cell function or insulin sensitivity.
- Published in:
- Diabetic Medicine, 2016, v. 33, n. 12, p. 1744, doi. 10.1111/dme.13033
- By:
- Publication type:
- Article
Real-world evidence of the effects of sodium-glucose co-transporter 2 inhibitors on the dosing of diuretics in patients with heart failure: a retrospective cohort study.
- Published in:
- Frontiers in Pharmacology, 2024, p. 1, doi. 10.3389/fphar.2024.1366439
- By:
- Publication type:
- Article
Emerging role of antidiabetic drugs in cardiorenal protection.
- Published in:
- Frontiers in Pharmacology, 2024, p. 1, doi. 10.3389/fphar.2024.1349069
- By:
- Publication type:
- Article
m6A eraser FTO modulates autophagy by targeting SQSTM1/P62 in the prevention of canagliflozin against renal fibrosis.
- Published in:
- Frontiers in Immunology, 2023, v. 13, p. 01, doi. 10.3389/fimmu.2022.1094556
- By:
- Publication type:
- Article
Canagliflozin reverses Th1/Th2 imbalance and promotes podocyte autophagy in rats with membranous nephropathy.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.993869
- By:
- Publication type:
- Article
Gut Microbiota and Antidiabetic Drugs: Perspectives of Personalized Treatment in Type 2 Diabetes Mellitus.
- Published in:
- Frontiers in Cellular & Infection Microbiology, 2022, v. 12, p. 1, doi. 10.3389/fcimb.2022.853771
- By:
- Publication type:
- Article
Association of type III collagen turnover with cardiovascular outcomes and impact with canagliflozin in the CANVAS Program: A post hoc analysis.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 9, p. 4060, doi. 10.1111/dom.15761
- By:
- Publication type:
- Article
Time trends and regional variation in utilization of antidiabetic medicines in China, 2015–2022.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 7, p. 2752, doi. 10.1111/dom.15594
- By:
- Publication type:
- Article
Patterns of initial and first‐intensifying antidiabetic drug utilization among patients with type 2 diabetes mellitus in Scotland, 2010–2020: A retrospective population‐based cohort study.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 7, p. 2684, doi. 10.1111/dom.15584
- By:
- Publication type:
- Article
Ethnic disparities in cardiovascular and renal responses to canagliflozin between Asian and White patients with type 2 diabetes mellitus: A post hoc analysis of the CANVAS Program.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 3, p. 878, doi. 10.1111/dom.15380
- By:
- Publication type:
- Article
Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 2, p. 758, doi. 10.1111/dom.15340
- By:
- Publication type:
- Article
Diabetes, antidiabetic medications and risk of dementia: A systematic umbrella review and meta‐analysis.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 2, p. 441, doi. 10.1111/dom.15331
- By:
- Publication type:
- Article
The effects of canagliflozin in type 2 diabetes in subgroups defined by population‐specific body mass index: Insights from the CANVAS Program and CREDENCE trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 12, p. 3724, doi. 10.1111/dom.15267
- By:
- Publication type:
- Article
Cost‐effectiveness of canagliflozin and dapagliflozin for treatment of patients with chronic kidney disease and type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 10, p. 3030, doi. 10.1111/dom.15201
- By:
- Publication type:
- Article
Mediators between canagliflozin and renoprotection vary depending on patient characteristics: Insights from the CREDENCE trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 10, p. 2944, doi. 10.1111/dom.15191
- By:
- Publication type:
- Article
Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 8, p. 2331, doi. 10.1111/dom.15112
- By:
- Publication type:
- Article
The sodium‐glucose cotransporter‐2 inhibitor canagliflozin does not increase risk of non‐genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double‐blind trials
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 8, p. 2151, doi. 10.1111/dom.15091
- By:
- Publication type:
- Article
Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: Integrated analysis from the CANVAS Program and CREDENCE trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 2043, doi. 10.1111/dom.15065
- By:
- Publication type:
- Article
Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS programme and CREDENCE.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 2038, doi. 10.1111/dom.15057
- By:
- Publication type:
- Article
Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 5, p. 1413, doi. 10.1111/dom.14978
- By:
- Publication type:
- Article
Oral insulin (ORMD‐0801) in type 2 diabetes mellitus: A dose‐finding 12‐week randomized placebo‐controlled study.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 4, p. 943, doi. 10.1111/dom.14901
- By:
- Publication type:
- Article
Canagliflozin reduces proteinuria by targeting hyperinsulinaemia in diabetes patients with heart failure: A post hoc analysis of the CANDLE trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 2, p. 354, doi. 10.1111/dom.14876
- By:
- Publication type:
- Article
Ethnic and socioeconomic disparities in initiation of second‐line antidiabetic treatment for people with type 2 diabetes in England: A cross‐sectional study.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 1, p. 282, doi. 10.1111/dom.14874
- By:
- Publication type:
- Article
Canagliflozin, mental health adverse events and diabetes: Exploratory analysis of the CREDENCE trial and CANVAS Program.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 12, p. 2459, doi. 10.1111/dom.14832
- By:
- Publication type:
- Article
Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: Results from the LixiLan‐L‐CN randomized controlled trial
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 11, p. 2182, doi. 10.1111/dom.14803
- By:
- Publication type:
- Article
Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta‐analysis.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 10, p. 1927, doi. 10.1111/dom.14772
- By:
- Publication type:
- Article
Mechanisms of action of the sodium‐glucose cotransporter‐2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 10, p. 1950, doi. 10.1111/dom.14779
- By:
- Publication type:
- Article